A highly aggressive human CALLA+Cp+ pre-B acute lymphoblastic leukemia (ALL) cell line (NALM-6-UM1) causes disseminated and invariably fatal leukemia in CB.17 mice with severe combined immunodeficiency (SCID). We used this SClD mouse model of human pre-B ALL t o evaluate and compare, in a total of 434 SClD mice, the antileukemic efficacy of 843 (anti-CD19)-pokeweed antiviral protein (PAP) immunotoxin and cyclophosphamide (CPA) as individual reagents and as combined immunochemotherapeutic regimens. B43-PAP plus CPA was superior t o either the immunotoxin or drug alone, and combined immunochemotherapy markedly improved the event-free survival (EFS) of SClD mice challenged with NALM-6-UM1 pre-B ALL cells. Notably, (median survival, 58 days) nor 1 mg CPA (median survival, 49 days) resulted in long-term EFS of SClD mice challenged with 5 x lo6 NALM-6-UM1 pre-B ALL cells, the probability of EFS at 6 months was 50% f 16% for SClD mice treated with 15 pg B43-PAP plus 1 mg CPA (median survival, >180 days) (P < .Owl). The probability of long-term EFS was only 14% f 7% for mice treated with 30 pg B43-PAP and 0% f 0% for mice treated with 1 mg CPA, but 40% f 16% for mice treated with 30 pg B43-PAP plus 1 mg CPA (P c .Owl). Similarly, the CUTE LYMPHOBLASTIC leukemia (ALL) is an A immunophenotypically and biologically heterogeneous group of diseases.'s2 Multiagent chemotherapy and effective central nervous system prophylaxis have resulted in prolonged disease-free survival in the majority of patients with ALL.3 However, a group of patients who can be identified at diagnosis remain at high risk for treatment failure and early r e l a p~e .~ CD19+sIg-B-cell precursor ALL is the most common form of ALL in both children and
A highly aggressive human CALLA+Cp+ pre-B acute lymphoblastic leukemia (ALL) cell line (NALM-6-UM1) causes disseminated and invariably fatal leukemia in CB.17 mice with severe combined immunodeficiency (SCID). We used this SClD mouse model of human pre-B ALL t o evaluate and compare, in a total of 434 SClD mice, the antileukemic efficacy of 843 (anti-CD19)-pokeweed antiviral protein (PAP) immunotoxin and cyclophosphamide (CPA) as individual reagents and as combined immunochemotherapeutic regimens. B43-PAP plus CPA was superior t o either the immunotoxin or drug alone, and combined immunochemotherapy markedly improved the event-free survival (EFS) of SClD mice challenged with NALM-6-UM1 pre-B ALL cells. Notably, 90% t o 100% of SClD mice challenged with 1 x lo6 leukemia cells and then treated with B43-PAP plus CPA combined immunochemotherapy regimens became long-term survivors, a result not achieved with B43-PAP alone or CPA alone. The advantage was particularly evident in mice inoculated with 5 x lo6 leukemia cells. While neither 15 p g B43-PAP (median survival, 58 days) nor 1 mg CPA (median survival, 49 days) resulted in long-term EFS of SClD mice challenged with 5 x lo6 NALM-6-UM1 pre-B ALL cells, the probability of EFS at 6 months was 50% f 16% for SClD mice treated with 15 pg B43-PAP plus 1 mg CPA (median survival, >180 days) (P < .Owl). The probability of long-term EFS was only 14% f 7% for mice treated with 30 pg B43-PAP and 0% f 0% for mice treated with 1 mg CPA, but 40% f 16% for mice treated with 30 pg B43-PAP plus 1 mg CPA (P c .Owl). Similarly, the
CUTE LYMPHOBLASTIC leukemia (ALL) is an
A immunophenotypically and biologically heterogeneous group of diseases.'s2 Multiagent chemotherapy and effective central nervous system prophylaxis have resulted in prolonged disease-free survival in the majority of patients with ALL.3 However, a group of patients who can be identified at diagnosis remain at high risk for treatment failure and early r e l a p~e .~ CD19+sIg-B-cell precursor ALL is the most common form of ALL in both children and
In pre-B ALL, which comprises approximately probability of EFS at 6 months was 40% f 16% for mice treated with 2 mg CPA alone, 70% k 15% for mice treated with 2 mg CPA plus 15 pg B43-PAP, and 70% 2 15% for mice treated with 2 mg CPA plus 30 p g B43-PAP. Ten SClD mice in the B43-PAP plus CPA combined immunochemotherapy arms surviving long term after the inoculation of 5 x lo6 NALM-6-UM1 pre-B ALL cells were electively killed at 174 t o 181 days t o assess their leukemia burden. We found no evidence of leukemia in any of the bone marrow specimens by two-color immunofluorescence and multiparameter flow cytometry. The percentage of CD19+, CD19+CD45+, CD19+CD10+, or CDlO+CD20+ human pre-B ALL blasts in the bone marrow of these 10 SClD mice was ~4 % . Most importantly, we found no molecular evidence of occult leukemia in any of the 10 long-term survivors analyzed when bone marrow, spleen, liver, or brain were examined for human pglobin gene sequences by polymerase chain reaction. Because a single NALM-6-UM1 cell causes disseminated and fatal leukemia in SClD mice within 150 days, the long-term EFS of SClD mice challenged with 5 x lo6 NALM-6-UM1 cells and subsequently treated with B43-PAP plus cyclophosphamide protocols is consistentwith 26.7 logs kill of clonogenic NALM-6-UM1 cells in vivo by combined immunochemotherapy. To our knowledge, this study is the first t o show the in vivo antileukemic efficacy of combined immunochemotherapy using an anti-CD19 immunotoxin plus CPA against CALLA/CDlO+Cp+slg-human pre-B ALL in a SClD mouse model system. 20% of B-cell precursor ALL cases, leukemic blasts express cytoplasmic Ig heavy chains (Cp) but lack surface Ig (sIg).I4 Pre-B ALL patients usually present with traditional high risk features, including high white blood cell (WBC) counts, DNA indices less than 1.16, elevated serum lactate dehydrogenase levels, and a pseudodiploid k a r y~t y p e .~-~ Pre-B-cell immunophenotype (CD19+Cp+sIg-) is associated with a significantly worse treatment outcome than Cp-Pre-pre-Bcell immunophenotype (CD19+Cp-sIg-), even after adjusting for the effects of known prognostic factor^.^,^ Effective chemotherapy for pre-B ALL may require the development of novel inductionJreinduction and maintenance protocols.
Immunotoxins (monoclonal antibody [MoAbI-toxin conjugates) are a new class of immunopharmacologic agents that shows considerable promise for more effective treatment of pre-B ALL. [8] [9] [10] [11] [12] [13] Immunotoxins have been prepared by covalently linking cell-type-specific MoAbs to a variety of catalytic toxins.*-13 Clonogenic blasts from pre-B ALL patients are very sensitive to immunotoxins targeted to the CD19 antigen.11J4-16 Therefore, we are among those who believe that anti-CD19 immunotoxins may provide an excellent opportunity to effectively eradicate therapyrefractory pre-B ALL blasts. Grossbard et a1 have prepared an anti-CD19 immunotoxin using blocked ricin (bR) as the toxin moiety and B4 anti-CD19 MoAb as the antibody moiety." Currently, B4-bR is under clinical investigation for treatment of B-lineage leukemias and 1ymph0mas.l~ Ghetie et a1 have constructed an anti-CD19 immunotoxin using deglycosylated ricin A chain as the toxin moiety and HD37 anti-CD19 MoAb as the antibody moiety.'* The same team has also prepared and tested anti-CD22 ricin A-chain immunotoxin in lymphoma patients.19 Our laboratory has prepared a series of anti-CD19 immunotoxins by covalently linking anti-CD19 MoAb B43 to different toxins, including pokeweed antiviral protein (PAP), recombinant ricin A chain, saporin, and m0m0rdin.l~ B43-PAP is an effective immunotoxin against CD19+ ALL blasts that is capable of killing in vitro greater than 99.9% of clonogenic blasts from pre-B ALL cell lines1lJ5 and from fresh bone marrow (BM) specimens of B-cell precursor ALL patients.14J6
More recently, we reported that a highly aggressive subclone of the human CALLA+Cp+pre-B ALL cell line NALM-6 (designated NALM-6-UM1) causes disseminated and fatal leukemia in CB.17 SCID mice.m We used this SCID mouse model of aggressive human pre-B ALL to evaluate the in vivo antileukemic efficacy of B43 (anti-CD19)-PAP immunotoxin.20 A 3-day treatment with nontoxin doses of B43-PAP markedly improved event-free survival (EFS) in SCID mice challenged with 1 x lo6 NALM-6-UM1 pre-B ALL cells. Based on these encouraging results and the in vitro efficacy of B43-PAP against clonogenic pre-B ALL b l a~t s ,~l ,~~-l~ we have recently initiated a phase I dose escalation study in relapsed pre-B/prepre-B ALL patients. Our clinical trial is being conducted under an Investigational New Drug Application approved by the Food and Drug Administration (FDA).
The purpose of the present study was to evaluate and compare the antileukemic capabilities of treatment regimens using B43-PAP immunotoxin, cyclophosphamide (CPA), or B43-PAP plus CPA in the NALM-6-UM1 SCID mouse model of human pre-B ALL. We report that combined immunochemotherapy using B43-PAP and CPA is superior to B43-PAP or CPA alone. The long-term EFS achieved by B43-PAP plus CPA in SCID mice challenged with otherwise lethal NALM-6-UM1 human pre-B ALL was consistent with 2 6.7 logs kill of clonogenic NALM-6-UMl cells in vivo. These experiments provide a paradigm to study the therapeutic potential of combined immunochemotherapy protocols using the SCID NALM-6-UM1 human pre-B ALL model. To our knowledge, this report is the first to examine and show the in vivo antileukemic efficacy of a combined immunochemotherapy regimen against CALLA+Ck+ human pre-B ALL in an SCID mouse model system.
MATERIALS AND METHODS

Cells.
The human NALM-6-UM1 pre-B ALL cell line20 was maintained by serial passages in RPMI 1640 medium (GIBCO Laboratories, Grand Island, NY) supplemented with 10% (vol/ vol) heat-inactivated fetal bovine serum (Hyclone Laboratories, Logan, UT) 50 pg/mL streptomycin, 50 IU/mL penicillin, 2 mmol/L L-glutamine, and 10 mmol/L HEPES buffer. Cells were cultured in tissue culture flasks at 37°C in a humidified 5% COz atmosphere. Before injection into SCID mice, cells were washed twice in phosphate-buffered saline (PBS) and resuspended in PBS. SCID mice were inoculated intravenously with 0.2 mL of this cell suspension containing 1 X 106 or 5 X lo6 NALM-6-UM1 cells.
PAP was isolated from spring leaves of pokeweed and purified by ion-exchange chromatography, as previously reported.21,22 PAP amino groups were thiolated using 2-iminothiolane, and modified PAP was mixed with SPDP-modified MoAb, using a 3.5:l molar ratio of PAP to MoAb to generate PAP immunotoxins in a sulfhydryl-disulfide exchange reaction. 22 The immunotoxins were initially purified by gel filtration high performance liquid chromatography to remove unreacted PAP and high molecular weight (> 300 Kd) conjugated/aggregates?2 Carboxymethyl (CM)-Sepharose ion-exchange chromatography was subsequently used to purify the immunotoxins from unconjugated MoAb, as previously described.22 B43 is a murine IgGk MoAb directed against the human CD19 antigen.= The procedures used for its large-scale production in a dedicated ACUSYST-Jr benchtop hollow-fiber cell culture system (Endotronics, Coon Rapids, MN), purification using the AfIi-Prep Protein A MAPS system (Bio-Rad Laboratories, Richmond, CA), and conjugation to PAP have been previously described in detai1.15~22 The B43-PAP immunotoxin preparation used in this study contained 56% 180 Kd (1:l PAP to MoAb ratio) immunotoxin species, 41% 210 Kd ( 2 1 PAP to MoAb ratio) immunotoxin species, 2.6% unconjugated B43 MoAb contamination, and 0.4% unconjugated PAP contamination.22 All quality control testing of B43-PAP was performed according to the Good Laboratory Practice regulations of the FDA, and the results were detailed in a previous report?2 B43-PAP Lot No. 1-1990-01 is approved by the FDA for human use in a phase I clinical trial (BB-IND 3864). G17.2 (antihuman CD4/T-helper subset, murine IgG1) was purified and linked to PAP, as previously rep0rted.2~ The chemical composition, ribosomeinhibitory activity, selective immunoreactivity, and cell-typespecific cytotoxicity of G17.2-PAP against CD4+ human T cells were previously described." G17.2-PAP was used as a control immunotoxin to confirm the selectivity of B43-PAP against NALM-6-UM1 pre-B ALL cells. CPA (Neosar manufactured by ASTA Pharma, Bielefeld, Germany) was obtained from Adria Laboratories (Division of Erbamont, Inc, Columbus, OH (2) . To prevent hemorrhagic cystitis, CPA-treated mice received Mesna. Mesna was diluted with PBS and administered intraperitoneally for the duration of the 3-day CPA treatment twice daily at total daily doses, which were equal to the total daily CPA doses. Controls included mice receiving PBS, unconjugated B43 MoAb, or G17.2 (anti-CD4)-PAP immunotoxin. Survival of mice was monitored by observation twice a day. Event times were measured from the day of inoculation of NALM-6-UM1 cells to the day of death. The probability of EFS was determined, and event-free interval curves were generated using the Kaplan-Meier product limit method, as previously reported. 20 We used the Mantel-Cox log-rank test to assess the effect of various treatment protocols on the probability of EFS of SCID mice inoculated with NALM-6-UM1 pre-B ALL cells, as previously r e p~r t e d .~~.~~ At the time of death, necropsies were performed and multiple organs of SCID mice were collected for evaluation of their human pre-B ALL leukemia burden.
Histopathologic and immunohistochemical analysis of SCID mouse tissues. For histopathologic and immunohistochemical studies, tissues were fixed in 10% neutral buffered formalin, dehydrated, and embedded in paraffin by routine methods. Glass slides with affixed 6-pm tissue sections were prepared and stained with hemotoqlin/eosin (H/E). Formalin-fixed, paraffin-embedded sections were evaluated immunohistochemically using the avidin-biotinperoxidase complex technique, as previously de~cribed.~' Antibodies used for immunohistochemical studies included LN3 (anti- Detection of human DNA in SCID mouse organs by polymerase chain reaction (PCR). Human DNA was detected by amplifying a 110-bp fragment from the first exon of the human p-globin gene using two 20-base oligonucleotide primers, PC03 and PC04, that flank the region to be amplified, as previously described in detaiLZO
Treatmentprotocols.
In brief, oligonucleotide primers (PC03: 5' ACA CAA CTG TGT TCA CTA GC 3' and PC04: 5' CAA CTA CAT CCA CGT TCA CC 3') were synthesized by the University of Minnesota Microchemical Facility using an Applied Biosystems Synthesizer (Foster City, CA). Human DNA was amplified using 0.5 to 1.0 pg genomic DNA with 1 U of Taq DNA polymerase (Perkin-Elmer Cetus, Norwalk, CT) in 1X PCR buffer (50 mmol/L KCl, 10 mmol/L Tris-C1, pH 8.3, 1.5 mmol/L MgC12, and 0.01% wt/vol gelatin) containing 0.75 pg of each primer and 200 pmol/L dNTPs (Pharmacia, Piscataway, NJ) in a total volume of 100 pL. Before amplification, samples were overlaid with 100 p L of mineral oil (Sigma, St Louis, MO). Sixty cycles were performed by incubating samples at 95°C for 1 minute, 55°C for 1 minute, and 72°C for 1 minute and 30 seconds, and by extending the 72°C elongation step for 2 seconds after each cycle and for 10 minutes after 60 cycles. To detect the PCRamplified human DNA, 12-pL aliquots of the PCR product were electrophoresed on 3% agarose gels in TAE buffer (0.04 mol/L Tris-acetate and 0.001 mol/L EDTA). The gels were stained in 0.0002% ethidium bromide solution and visualized with a UV transilluminator. Photographs of the gels were taken with a Polaroid MP-4 camera using type 55 film (Fotodyne Co, New Berlin, WI). Controls included the PCR reaction buffer without the genomic DNA as a negative background control (NEG CON l), the PCR reaction mixture with SCID mouse DNA from BM, spleen, liver, and brain from an SCID mouse that had not been inoculated with human ALL cells as an additional negative control (NEG CON 2), and the PCR reaction mixture with NALM-6-UM1 pre-B ALL cell line genomic DNA as a positive control (POS CON). The specificity of the PCR products in 1-pg genomic SCID mouse DNA samples was confirmed by Southern blot hybridization analysisZo using RS06, an oligonucleotide probe (CTGACTCCT-GAGGAGAAGT~GCCGTTACTGCCCCTG) hybridizing to the central region of the 110-bp fragment produced by PC03 and PC04. In brief, 12-pL aliquots of the PCR products were electrophoresed on 3% agarose gels in TAE buffer. Gels were denatured for 30 minutes in 1.5 mol/L NaCl and 0.5 N NaOH followed by neutralization in 0.5 mol/L Tris-C1, pH 7.4, plus 1.5 mol/L NaC1. The PCR products were transferred to Nytran (Schleicher & Schuell, Keene, NH) membrane using capillary action in 20X SSC overnight. The DNA was crosslinked to the membrane by a stratalinker (Stratagene, La Jolla, CA) after which the blot was prehybridized in 25 mL 6X SSPE (1X SSPE is 0.18 mol/L NaCI, 10 mmol/L NaH2P04, 1 mmol/L EDTA, pH 7.4), 0.5% sodium dodecyl sulfate (SDS), 1OX Denhardt's, 50 pg/mL salmon sperm DNA, and 10 pg/mL tRNA for 4 hours at 42°C. Hybridization was for 16 hours at 42°C in 25 mL of 50% formamide, 6X SSPE, 0.5% SDS, 50 pg/mL salmon sperm DNA, and 10% Dextran sulfate containing lo6 cpm/mL [y-32P]-ATP-labeled RS06 probe, as previously reported.20 (Fig 1) and leukemic infiltrates were found in the spleen and liver, as well as in perirenal/ periadrenal soft tissues in most cases (Fig 1) . Histopathologic examination of BM showed densely packed leukemic blasts with prominent nucleoli and high mitotic activity, which in most cases had penetrated the cortex of the bone and infiltrated adjacent skeletal muscle. Immunohistochemical examination of BM sections using the avidin-biotinperoxidase complex techinque confirmed that virtually all normal SCID mouse BM cells in the medullary cavity were replaced by CD45+HLA-DR+ human leukemic blasts (Fig   2) . Leptomeninges of the brain contained rafts of leukemic blasts that extended into the Virchow-Robin spaces. The red pulp of spleens contained multifocal or diffuse leukemic infiltrates and accumulations of leukemic blasts appeared in the sinusoids of the livers. The other affected tissues were infiltrated by solid sheets of leukemic blasts.
RESULTS
NALM-6-UMI human pre-B ALL cells cause disseminated
Multiparameter flow cytometric analysis of SCID mouse BM specimens confirmed the presence of CALLA/ CDlO+CD19+ human pre-B ALL blasts (Fig 3) . PCR amplication of a 110-bp DNA fragment from the first exon of the human P-globin gene further confirmed the presence For personal use only. on October 23, 2017. by guest www.bloodjournal.org From of human origin DNA in BM, spleen, lymph nodes, liver, brain, kidney, perirenal soft tissue, adrenal gland, and periadrenal fat of SCID mice challenged with NALM-6-UM1 pre-B ALL cells (Fig 4B and C) . In contrast, no human @-globin gene sequences were detected in SCID mouse DNA with no or less than 0.1% human DNA contamination ( Fig 4A) .
As reported earlier,20 cytogenetic analysis of BM cells at the time of leukemic death showed the same numerical as well as complex structural chromosomal abnormalities in all cells examined [20=47,X,-Y,-1,-3,-5,-10,dir dup (3)(q13-q27), ?del (14) (q22q24), +?del (14)(q22q24), dir dup (18) (q21), t(8;14)(q24;q32), t(9;15)(q32;q26), +der (1) ins (l;?) (p34;?) inv dup (1) (q25-q12), +der (3) t(3;?) (pll;?), +2der (5)t(5;?) (qll;?), +der (10) 
9.4/CD45 (FITC)
6-UM1 SCID mouse model was used to compare the antileukemic efficacy of B43-PAP immunotoxin and CPA. A total of 434 SCID mice were used in these experiments (Table 1 ). All 27 PBS-treated control SCID mice challenged intravenously with 1 x lo6 NALM-6-UMl pre-B ALL cells died at 24 to 54 days after inoculation with a median EFS of 39 days. The Kaplan-Meier estimate (2SE) of the probability of EFS was 85% 2 7% at 1 month but 0% k 0% at 3 or 6 months (Table 1 and Fig 5A) . Importantly, treatment with B43-PAP significantly improved EFS of SCID mice challenged with 1 x lo6 NALM-6-UMl pre-B ALL cells. Significantly higher cumulative proportions of B43-PAP-treated SCID mice remained alive without evidence of leukemia as compared with PBS-treated SCID mice (P value < .000001 for 5 to 30 pg B43-PAP).
The Kaplan-Meier estimates (eSE) of the probability of EFS at 6 months after inoculation of NALM-6-UM1 cells were 65% 2 10% for SCID mice treated with a total of 15 pg B43-PAP, 70% 2 10% for SCID mice treated with a total of 20 pg B43-PAP, and 67% k 10% for SCID mice treated with a total of 30 pg B43-PAP (Table 1 and Fig 5A) . Similar results were obtained in mice challenged with 5 x 106 NALM-6-UM1 cells. All of the 24 PBS-treated control mice inoculated with 5 x lo6 NALM-6-UM1 cells died of leukemia, with a median survival time of 30 days (Table 1 and Fig 5B) . B43-PAP improved survival and significantly higher cumulative proportions of B43-PAP-treated SCID mice remained alive without evidence of leukemia as CON 1) ; the PCR reaction mixture with SClD mouse DNA from BM, spleen, liver, and brain from an SClD mouse that had not been inoculated with human ALL cells as an additional negative control (NEG CON 2); and the PCR reaction mixture with NALM-6-UM1 pre-B ALL cell line genomic DNA as a positive control (POS CON). The specificity of the PCR products was confirmed by Southern blot hybridization analysis using RS06, an oligonucleotide probe (CTGACTCCTGAGGAGAAGTCTGCCGTTACT-GCCCTG) hybridizing t o the central region of the fragment produced by PC03 and PC04.
For compared with PBS-treated SCID mice (Pvalue < .OooOOl for 15 pg, 20 pg, as well as 30 pg B43-PAP). The KaplanMeier estimate ( S E ) of the probability of EFS for SCID mice treated with a total of 30 pg B43-PAP was 26% 2 8% at 3 months and 14% f 7% at 6 months after inoculation of NALM-6-UM1 cells (Table 1 and Fig 5B) . Total doses of B43-PAP ranging from 5 pg (-0.3 mg/kg) to 30 pg (2 mg/kg) were well tolerated by SCID mice, with no apparent signs of toxicity and no drug-related histopathologic lesions in any particular organ. However, 45 Fg (3 mg/kg) B43-PAP, a dose that represents only an LDl0 dose (ie, a dose that kills 10% of all treated mice) in normal BALB/c was highly toxic to SCID mice. All 10 SCID mice in this dose group died of necrotizing myocarditis and acute tubular necrosis at a median of 16 days (Table l) , with no evidence of leukemia, as determined by PCR analysis of BM, spleen, liver, and brain specimens (data not shown). In contrast to B43-PAP, neither unconjugated B43 MoAb at 30 pg total dose nor the control imqpnotoxin G17.2 (anti-CD4)-PAP at 30 pg total dose displayed significant antileukemic activity against NALM-6-UM1 cells (Table 1 and Fig 5A  and B) . CPA displayed a dose-dependent antileukemic activity against NALM-6-UM1 pre-B ALL in vivo. In SCID mice inoculated with 1 x lo6 leukemia cells, 200 pg ( -13 mg/kg) or 1 mg ( -67 mg/kg) total dose of CPA was not as effective as 5 to 30 pg of B43-PAP, but 2 mg total dose ( -133 mg/kg) yielded comparable results. The KaplanMeier estimates (+SE) of the probability of EFS for SCID mice challenged with 1 x 106 NALM-6-UM1 leukemia cells and then treated with 2 mg CPA were 100% f 0% at 1 month, 90% f 10% at 3 months, and 80% f 13% at 6 months (Table 1 and Fig 6A) . In SCID mice inoculated with 5 x lo6 leukemia cells, 50 to 100 pg doses of CPA were not effective. Indeed, the median survival times were shorter in these treatment groups than in PBS-treated mice (Table l) , perhaps secondary to rapid progression of pre-B ALL in SCID mice further immunosuppressed by CPA therapy. By comparison, CPA doses ranging from 200 pg to 2 mg displayed a dose-dependent antileukemic activity ( Fig 6B) . As compared with 30 pg B43-PAP, 50 pg to 1 mg doses of CPA were less effective, but 2 mg CPA was more effective. The Kaplan-Meier estimate (2 SE) of the probability of EFS at 6 months after inoculation of 5 x 106 NALM-6-UM1 cells was 40% 2 16% for SCID mice treated with 2 mg CPA, but only 15% f 7% for SCID mice treated with 30 pg B43-PAP (Table 1 and Figs 5 and 6 ). Combined immunochemotherapy of NALM-6-UMl human pre-B ALL in SCID mice using B43-PAP immunotoxin plus CPA. Previous studies have shown that the in vitro active CPA congener mafosfamid markedly enhances the in vitro antileukemic activity of B43-PAP immunotoxin against B-lineage ALL cell^.^ Therefore, we examined the in vivo antileukemic efficacy of regimens containing B43-PAP plus CPA against NALM-6-UM1 human pre-B ALL in SCID mice. Notably, the combination of 15 pg or 30 pg B43-PAP with 1 or 2 mg CPA was more effective against NALM-6-UM1 leukemia than B43-PAP or CPA alone. As shown in Table 1 , 90% to 100% of SCID mice challenged with 1 x lo6 leukemia cells and then treated with B43-PAP plus CPA became long-term survivors, a result not achieved by B43-PAP or CPA alone. The advantage of combihed immunochemotherapy regimens was particulary evident in mice challenged with 5 x lo6 leukemia cells. While neither 15 pg B43-PAP (median survival, 58 days) nor 1 mg CPA (median survival, 49 days) resulted in long-term EFS of SCID mice challenged with 5 x lo6 NALMQ-UM1 pre-B ALL cells, the probability of EFS at 6 monthi was 50% +-16% for SCID mice treated with 15 pg B43-PAP plus 1 mg CPA (median survival, 160 days) (P < .0001) (Fig 7) . The probability of long-term EFS was only 15% 2 7% for mice treated with 30 pg B43-PAP, 0% f 0% for mice treated with 1 mg CPA, but 40% +-16% for mice treated with 30 kg B43-PAP plus 1 mg CPA (P < .OOOl) ( Table 1 and Fig 7) .
Similarly, the probability of EFS at 6 months after inoculation with 5 x lo6 NALM-6-UM1 cells was 40% 2 16% for mice treated with 2 mg CPA alone, 70% 2 15% for mice treated with 2 mg CPA plus 15 pg B43-PAP, and 70% 2 15% for mice treated with 2 mg CPA plus 30 pg B43-PAP ( Table 1 and Fig 7) . Analysis of leukemia burden in long-term surviving SCID mice. Ten long-term surviving SCID mice who received B43-PAP plus CPA after inoculation of 5 x lo6 NALM-6-UM1 pre-B ALL cells were electively killed at 174 to 181 days to assess their leukemia burden. We found no evidence of leukemia in any of the nine long-term survivors whose BM specimens were analyzed by two-color immunofluorescence and multiparameter flow cytometry ( Table  2 ). The percentage of CD19+, CD19+CD45+, CD19+CD10+, or CDlO+CD20+ human pre-B ALL blasts in the BM of these SCID mice was 1 4 % ( Table 2 ). Most importantly, we found no molecular evidence of occult leukemia in any of the 10 long-term survivors analyzed with their BM, spleen, liver, or brain were examined for human P-globin gene sequences by PCR (Table 2 and Fig 8) . Similarly, no flow cytometric or PCR evidence of occult leukemia was found in one long-term survivor (SCID mouse no. 0927; Table 2 and Fig 7) treated with 30 kg B43-PAP alone or in two long-term survivors (SCID mice nos. 0871 and 0880) treated with 2 mg CPA. By comparison, all of the remaining 13 mice in the PBS (N = 4), 15 kg B43-PAP (N = 4), 30 kg B43-PAP (N = 2), or 1 mg CPA (N = 3) treatment groups, who died of leukemia and were included in these analyses as controls, showed flow cytometric and/or PCR evidence of leukemia (Table 2 and Fig 8) .
DISCUSSION
CPA, the prototype of a group of alkylating agents generally referred to as oxazaphosphorines, had broad applications as an anti-neoplastic and immunosuppressive agent31-35 since its development three decades ago by Arnold et al.30 In ALL, CPA has a remission induction capability similar to methotrexate, 6-mercaptopurine, and ~ytarabine?'-~~ CPA has been used clinically in (1) chemotherapy trials for poor prognosis ALL as part of induction, consolidation, maintenance, and delayed inten~ification~~; and (2) BM transplantation (BMT) trials for high-risk ALL in second or subsequent remission as part of pretransplant conditioning regimen^.^'-^ Notably, the in vitro active CPA congener mafosfamid was found to markedly enhance the in vitro antileukemic activity of immunotoxins containing PAP h e m i t o~i n ,~~,~' ricin A or intact ricin toxin.43 Based on these results, clinical autologous BMT protocols at the University of Minnesota use immunotoxins in combination with 4-hydroperoxycyclophosphamide for ex vivo purging of auto graft^.^^-"^ In a human leukemia/lymphoma subcutaneous xenograft model system, we found that combined immunotoxin plus mafosfamid regimens were more effective than immunotoxins or mafosfamid alone. 47 The CD19 antigen displays exquisite B-lineage specificity, undergoes antibody-induced internalization, and is expressed on the majority of clonogenic pre-B ALL blast^.^,^,^^ Extensive studies by our laboratory, as well as by several other laboratories participating in the International Workshops on Human Leukocyte Differentiation Antigens, have provided unambiguous evidence that CD19 is not expressed in nonlymphohematopoietic ti~sues.2~ The antigen is expressed by virtually 100% of pre-B ALL cases, is present at high density on each leukemic pre-B ALL blast, and undergoes internalization upon binding to anti-CD19 MOA^.^,^^ B43-PAP, an immunotoxin constructed by covalently thinking the anti-CD19 MoAb B43 to the plant hemitoxin PAP, is a highly effective antileukemic agent against pre-B ALL blasts.14-16
In a recent study, we learned that the CD19+Cy+sIg-human pre-B ALL cell line NALM-6-UM1 causes disseminated and invariably fatal leukemia in immunodeficient SCID mice.20 This model system'of disseminated human pre-B ALL was used to examine the in vivo antleukemic efficacy of B43 (anti-CD19)-PAP immunotoxin.20 In the present study, we used the same in vivo model to compare the antileukemic efficacy of B43-PAP immunotoxin and CPA as individual reagents and as combined immunochemotherapeutic regimens. We show that combined immunochemotherapy using B43-PAP and CPA is superior to either B43-PAP or CPA alone and markedly improves EFS of SCID mice challenged with NALM-6-UM1 pre-B ALL cells. Ninety to 100% of SCID mice challenged with 1 x 106 The 110-bp human p-globin gene fragment was PCR amplified in the genomic 1 pg DNA samples from long-term surviving SClD mice that were electively killed 6 months after inoculation of 5 x lo6 NALM-6-U M l cells, and the specificity of the PCR products was confirmed by Southern blot hybridization analysis using RS06, an oligonucleotide probe, as in (A 5 x lo6 NALM-6-UM1 pre-B ALL cells, the probability of EFS at 6 months was 50% for SCID mice treated with 15 pg B43-PAP plus 1 mg CPA (P < .OOOl). The probability of long-term EFS was 15% for mice treated with 30 pg B43-PAP, 0% for mice treated with 1 mg CPA, and 40% for mice treated with 30 Fg B43-PAP plus 1 mg CPA (P < .mol). Similarly, the probability of EFS at 6 months after inoculation with 5 X lo6 NALM-6-UM1 cells was 40% for mice treated with 2 mg CPA, 70% for mice treated with 2 mg CPA plus 15 pg B43-PAP or 2 mg CPA plus 30 pg B43-PAP. Most importantly, we found no molecular evidence of occult leukemia in any of the 10 long-term survivors analyzed when BM, spleen, liver, and brain were examined for human P-globin gene sequences by PCR. Because a single NALM-6-UM1 cell causes disseminated and fatal leukemia in SCID mice within 150 days,m the long-term EFS of SCID mice challenged with 5 x 106 N a M -6 -U M 1 cells and subsequently treated with B43-PAP plus CPA protocols is consistent with 16.7 logs kill of clonogenic NALM-6-UM1 cells in vivo by combined iqmunochemotherapy.
The reasons for this therapeutic advantage remain unknown, but several interactive mechanisms could contribute to the increased antitumor efficacy of combined immp nochemotherapy protocols. For example, B43-PAP immunotoxin aand CPA are highly potent antileukemic agents that interfere at different levels of the cellular machinery. B43-PAP kills target leukemia cells by inhibiting protein whereas CPA (via its active metabolite phospharamide mustard) kills cells by RNA alkylation and cell cycle arrest?' Therefore, a combination is likely to be more effective than either agent alone. Active CPA metabolites may influence the chemical processing of B43-PAP in the cytoplasm by altering the pH of the lysosomal microenvironment. Alternatively, B43-PAP may accelerate the rate at which 4-hydroxycyclophosphamide is converted to phospharamide mustard by altering the concentration and efficacy of the bases that catalyze the reaction, or it may enhance the toxicity of 4-hydoxycyclophosphamide by decreasing the aldehyde dehydrogenase activity.5°151 Binding of immunotoxin molecules to Kupfer cells of the liver via the Fc-receptors might possibly trigger metabolic changes in the liver that alter CPA pharmacokinetics by modulating the hepatic microsomal mixedfunction oxygenase activity?* While the mechanisms involved require elucidation, the superb antileukemic efficacy of B43-PAP immunotoxin combined with CPA in our SCID mouse model of human pre-B ALL clearly illustrates the potential of this combined immunochemotherapeutic approach for therapy of refractory or relapsed pre-B ALL.
To our knowledge, this study is the first to show the in vivo antileukemic efficacy of combined immunochemotherapy using an anti-CD19 immunotoxin plus CPA against CALLA/CDIO+Cp+sIg-human pre-B ALL in a SCID mouse model system. Future comparative analyses of various anti-B-cell immunotoxins and combined immunochemotherapy protocols using anti-CD19 immunotoxins in this model may provide the basis for designing more effective treatment against pre-B ALL.
NKC: Developmental hierarchy during early human B-cell ontogeny after autologous bone marrow transplantation using autografts depleted of CD19+ B-cell precursors by an anti-CD19 pan-B-cell immunotoxin containing pokeweed antiviral protein. 
